ITPP
Myo-inositol trispyrophosphate · Oxygen-release enhancer (research chemical)
What it is
A compound that shifts hemoglobin's oxygen curve so tissues extract more oxygen — developed in academic labs for heart-failure and cancer contexts, adopted by endurance-doping circles and horse racing before humans got vials of it.
How it works
ITPP (myo-inositol trispyrophosphate) works on haemoglobin rather than on muscle or metabolism. It acts as an allosteric effector that shifts haemoglobin's oxygen-binding curve, making it release oxygen to tissue more readily. The intended application was medical — improving oxygen delivery in hypoxic tumours and in heart failure — and the performance interest follows the same logic: more oxygen released to working muscle. It also appears in horse racing doping cases, which is where much of the public awareness comes from.
What human evidence shows
Animal studies (including the equine doping record — it was a horse-racing scandal drug first) and early oncology interest. Human performance data: none published. The mechanism is real biochemistry; the human dose-response is guesswork.
The studies, one by one
- LIMITED and confined to oncology settings. A phase Ib dose-escalation study evaluated it as a hypoxia modifier in cancer patients, and a related compound was developed for the same purpose in liver conditions.
- NONE SHOWN for athletic performance in humans. No trial has tested that application, and the oncology dose-escalation work does not address it.
- The theoretical concern with shifting the oxygen curve is that it is a systemic change to how oxygen is delivered everywhere, not just to the muscle someone wants to work — and the consequences of that in a healthy person exercising hard have not been studied.
- It is prohibited in sport as a substance affecting oxygen delivery, and it has featured in equine doping enforcement.
- Sold as research-chemical supply of unverified identity and purity.
Half-life and how long it lasts
Given by injection in the studies that exist. Human pharmacokinetics beyond the oncology programme are poorly characterised. Effects on the oxygen dissociation curve are the measurable property; what dose produces what shift in a healthy person, and for how long, is not established.
Risks
Uncharacterized human safety plus a mechanism that interacts with oxygen-sensing systems the body regulates tightly. Anti-doping detection methods exist, and it falls under WADA's prohibition of artificial enhancement of oxygen uptake, transport, or delivery.
Who should never touch it
- Anyone in tested sport, where it is prohibited
- Anyone with cardiovascular or respiratory disease
- Anyone using injectable grey-market product, given sterility risk
- Anyone pregnant or breastfeeding
Interactions worth knowing
- No characterised human interaction profile exists for non-oncology use.
- Anything affecting oxygen delivery or haemoglobin, including altitude exposure and blood manipulation, on mechanistic grounds.
- Tested sport, where it is prohibited.
What a clinician would watch
- There is no established monitoring for performance use, because the application has never been studied.
- Anyone using an injectable grey-market product faces sterility risk regardless of the compound.
- Cardiovascular symptoms during exertion, given that this alters oxygen delivery systemically while the heart is under load.
- Anti-doping status for anyone competing, where it is prohibited.
What stopping looks like
The effect on haemoglobin's oxygen-binding curve reverses as the compound clears. No withdrawal syndrome is described. Since no performance benefit has been established in humans, there is no demonstrated effect to lose.
Myth vs evidence
“It is a legal alternative to blood doping.”
It is prohibited in sport specifically because it affects oxygen delivery, and no human performance trial exists to support the comparison.
“The cancer research proves it is safe.”
A phase Ib dose-escalation study in cancer patients establishes tolerability in that population at studied amounts for that purpose. It says nothing about a healthy person exercising hard.
“More oxygen to muscle is straightforwardly good.”
It shifts oxygen delivery systemically, and what that does under exercise load in a healthy person has never been studied.
Legal status
US: not FDA-approved for human use; prohibited in sport under WADA's oxygen-delivery rules.
Research on this compound
Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.
- ITPP in early pancreatic zebrafish xenografts mildly impacts tumor cell death without interfering with vascular normalization
- Cole O, King AA. iTPP: nature vs nurture? Blood. 2022;140(12):1329-1330
- Oxygen therapeutic window induced by myo-inositol trispyrophosphate (ITPP)-Local pO2 study in murine tumors
Evidence base
emerging literature
Real human evidence: randomised trial reports, or review-level evidence backed by at least one human trial report.
- phase 3/4
- 0
- randomised
- 1
- reviews
- 1
- human trials
- 3
Counts are of published papers, not distinct trials, and they nest rather than add up: PubMed files every randomised trial as a clinical trial too. They measure how much research exists — not whether this works or is safe for you.
Research (12)
- iTPP: nature vs nurture?Blood · 2022
- Cole O, King AA. iTPP: nature vs nurture? Blood. 2022;140(12):1329-1330Blood · 2023
- New potential treatment for cardiovascular disease through modulation of hemoglobin oxygen binding curve: Myo-inositol trispyrophosphate (ITPP), from cancer to cardiovascular diseaseBiomed Pharmacother · 2022
- Oxygen therapeutic window induced by myo-inositol trispyrophosphate (ITPP)-Local pO2 study in murine tumorsPLoS One · 2023
- The Allosteric Hemoglobin Effector ITPP Inhibits Metastatic Colon Cancer in MiceAnn Surg · 2017
- ITPP Treatment of RG2 Glioblastoma in a Rat ModelAnticancer Res · 2016
- Impact of myo-inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour modelsJ Cell Mol Med · 2019
- Detection of myo-inositol tris pyrophosphate (ITPP) in equine following an administration of ITPPDrug Test Anal · 2014
- ITPP in early pancreatic zebrafish xenografts mildly impacts tumor cell death without interfering with vascular normalizationBMC Cancer · 2026
- Treatment of hypoxia-dependent cardiovascular diseases by myo-inositol trispyrophosphate (ITPP)-enhancement of oxygen delivery by red blood cellsJ Cell Mol Med · 2020
- Tumour suppressor PTEN activity is differentially inducible by myo-inositol phosphatesJ Cell Mol Med · 2023
- Screening and confirmation of myo-inositol trispyrophosphate (ITPP) in human urine by hydrophilic interaction liquid chromatography high resolution / high accuracy mass spectrometry for doping control purposesDrug Test Anal · 2014
Turn ITPP into a plan that's yours
The info above is free. Membership makes it personal, the Coach answers questions about your exact stack, the Stack tracks it for you, and the Verified Sources shows you how to vet what you buy.
- ✓ AI Coach, ask anything about your stack. It does the dosing math, flags interactions, and tells you what to do next.
- ✓ Personal Stack, save your protocol, track it across devices, log doses, get a heads-up before a vial runs out.
- ✓ Verified Sources, the vetted reference for checking quality and sourcing, members only.
Cancel anytime · or save with $59.99/yr · Coach + Stack included